Response to expression of concern regarding VIGOR study.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMC066096PMID 16495387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

  2005cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper

• Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies Levels in Chronic Viral Hepatitis (B&C)

  2021cites this paper
• Corporations, high-stakes biomedical research, and research misconduct: yes they can (and sometimes do)

  2021cites this paper
• Germline determinants of colorectal cancer risk and outcome

  2017cites this paper
• Pharmaceuticals, Money, and the Health Care Organizational Field

  2016cites this paper
• How Pharmaceutical Marketing Is Embraced within Medicine’s Scholarly Literature by ALASTAIR MATHESON

  2016cites this paper
• The Disposable Author: How Pharmaceutical Marketing Is Embraced within Medicine's Scholarly Literature.

  2016cites this paper
• Hollow Hunt for Harms

  2016cites this paper
• Gastrointestinal Adverse Reactions from Ibuprofen

  2015cites this paper
• The US requirement to deposit trial data within a year is unworkable

  2013cites this paper
• Evolution of Translational Omics: Lessons Learned and the Path Forward

  2013cites this paper
• COMMITTEE ON THE REVIEW OF OMICS-BASED TESTS FOR PREDICTING PATIENT OUTCOMES IN CLINICAL TRIALS

  2012cites this paper
• Framing the Forum

  2012cites this paper
• Corporate versus Public Interests: Community Responsibility to Defend Scientific Integrity

  2011cites this paper
• A BITTER PILL TO SWALLOW: CANADIAN DRUG REGULATION

  2010cites this paper
• Dissemination and publication of research findings: an updated review of related biases.

  2010cites this paper
• Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals

  2009cites this paper
• Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals.

  2009cites this paper
• Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice

  2008cites this paper
• Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

  2008cites this paper
• The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.

  2007cites this paper
• Dealing with Scientific Misconduct in the Future ROLE OF EDITORS AND JOURNALS IN DETECTING AND PREVENTING SCIENTIFIC MISCONDUCT: STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS

  2007cites this paper
• Conflicts of interest and disclosures in publications.

  2007cites this paper
• Conflicts of Interest and Disclosures in Publications

  2007cites this paper
• Conflicts of Interest in Health Care: Who Guards the Guardians?

  2007cites this paper
• Role of editors and journals in detecting and preventing scientific misconduct: strengths, weaknesses, opportunities, and threats.

  2007cites this paper
• Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us About Social Epistemology

  2007cites this paper
• Framing the forum: medical ethics in large-scale, interventional respiratory clinical trials.

  2007cites this paper
• What Your Doctor Should Know about Statistics (but Perhaps Doesn't…)

  2007cites this paper
• Pain Management in Patients With Parsonage‐Turner Syndrome

  2006cites this paper
• Expression of concern reaffirmed.

  2006cites this paper
• Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.

  2006cites this paper
• COX-2 inhibitors and the thrombotic risk

  2006cites this paper
• Patient empowerment: rofecoxib revisited.

  2006cites this paper
• Clinical trial registries and publication of results — a primer

  2006cites this paper
• DO PHARMACEUTICAL COMPANIES SELECTIVELY REPORT CLINICAL TRIAL DATA

  2006cites this paper
• Peptic ulcer disease

  2002cites this paper